Evaluation of novel cathepsin-X inhibitors in vitro and in vivo and their ability to improve cathepsin-B-directed antitumor therapy

New therapeutic targets that could improve current antitumor therapy and overcome cancer resistance are urgently needed. Promising candidates are lysosomal cysteine cathepsins, proteolytical enzymes involved in various critical steps during cancer progression. Among them, cathepsin X, which acts sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitrović, Ana, Završnik, Janja, Mikhaylov, Georgy, Knez, Damijan, Pečar Fonović, Urša, Matjan Štefin, Petra, Butinar, Miha, Gobec, Stanislav, Turk, Boris, Kos, Janko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738504/
https://www.ncbi.nlm.nih.gov/pubmed/34989869
http://dx.doi.org/10.1007/s00018-021-04117-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738504/
https://www.ncbi.nlm.nih.gov/pubmed/34989869
http://dx.doi.org/10.1007/s00018-021-04117-w

Ejemplares similares